Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 8.6% year on year to ...
Amgen delivered a strong fourth quarter of 2025 and looks well-positioned to absorb the LOEs on Prolia, Xgeva, and Ravicti in ...
Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street ...
Investor's Business Daily on MSN
Amgen eyes buy zone after fourth-quarter beat as obesity studies mount
Amgen is running a number of studies of its obesity drug, MariTide.
Amgen Inc. ( AMGN) Q4 2025 Earnings Call February 3, 2026 4:30 PM EST ...
The Manila Times on MSN
Amgen's Q4 results beat expectations, shares rise modestly
AMGEN on Tuesday reported fourth-quarter financial results that came in ahead of Wall Street expectations, sending its shares modestly higher as the company continues to express confidence in ...
By Deena Beasley Feb 3 (Reuters) - Amgen on Tuesday reported fourth-quarter financial results that came in ahead of Wall ...
Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its investigational obesity drug MariTide will continue to provide competitive weight ...
Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, Bernstein ...
Feb 3 (Reuters) - Amgen on Tuesday reported fourth-quarter financial results that came in ahead of Wall Street expectations, ...
Amgen on Tuesday reported fourth-quarter financial results that came in ahead of Wall Street expectations, sending its shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results